Lupus Nephritis Clinical Trials

4 recruiting

Frequently Asked Questions

Common questions about Lupus Nephritis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus ErythematosusLupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07236762
Recruiting
Phase 1Phase 2

Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.

Refractory Lupus NephritisSystemic SclerosisPrimary Sjogren's Syndrome Combined With Pulmonary Hypertension
Beijing GoBroad Hospital45 enrolled1 locationNCT06947473
Recruiting
Phase 1

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Sjogren's Syndrome (SS)+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07123519
Recruiting
Phase 1Phase 2

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

Refractory Lupus NephritisSystemic SclerosisPrimary Sjogren's Syndrome Combined With Pulmonary Hypertension
Beijing GoBroad Hospital45 enrolled1 locationNCT06947460
Recruiting

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Multiple SclerosisRheumatoid Arthritis (RA)Dermatomyositis+4 more
Kyverna Therapeutics70 enrolled1 locationNCT07403188
Recruiting
Phase 1Phase 2

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Systemic Lupus ErythematosusLupusAutoimmune Disorders+2 more
M.D. Anderson Cancer Center47 enrolled2 locationsNCT06434363
Recruiting

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

Kidney DiseasesDiabetic NephropathyKidney Failure, Chronic+2 more
The Rogosin Institute2,000 enrolled1 locationNCT01802034
Recruiting
Phase 2

SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease

Chronic Kidney DiseasesLupus Nephritis
The University of Hong Kong150 enrolled1 locationNCT06155604
Recruiting

High Quality Evidence of Guangzhou Lupus Nephritis Cohort (HOPE Cohort)

Lupus Nephritis (LN)
First Affiliated Hospital, Sun Yat-Sen University5,000 enrolled1 locationNCT06682507
Recruiting
Phase 1Phase 2

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)

Systemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisSjogren's Syndrome+6 more
Essen Biotech75 enrolled1 locationNCT06350110